X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PulmoStem
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PulmoStem
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $6.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 12, 2021
Details:
The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RES030-085
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RES030-085
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Agreement May 20, 2021
Details:
The agreement focuses on the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
